Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

被引：0

作者：

Pascal Urwyler

Panteleimon Charitos

Stephan Moser

Ingmar A. F. M. Heijnen

Marten Trendelenburg

Reto Thoma

Johannes Sumer

Adrián Camacho-Ortiz

Marcelo R. Bacci

Lars C. Huber

Melina Stüssi-Helbling

Werner C. Albrich

Parham Sendi

Michael Osthoff

机构：

[1] University Hospital Basel,Division of Internal Medicine

[2] University Hospital Basel,Division of Medical Immunology, Laboratory Medicine

[3] University of Basel,Department of Clinical Research and Department of Biomedicine

[4] Cantonal Hospital St. Gallen,Division of Infectious Diseases and Hospital Epidemiology

[5] Universidad Autónoma de Nuevo León,Hospital Universitario Dr. José Eleuterio González, Facultad de Medicina

[6] Centro Universitário em Saúde do ABC,Department of General Practice

[7] City Hospital Triemli,Clinic for Internal Medicine

[8] University Hospital Basel,Department of Infectious Diseases and Hospital Epidemiology

[9] Institute for Infectious Diseases,undefined

[10] University of Bern,undefined

来源：

Trials | / 22卷

关键词：

COVID-19; randomized trial; protocol; C1 esterase inhibitor; complement system; kallikrein kinin system; contact activation system;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 26 条

[21] Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study
John P. Haran
Jose C. Pinero
Yan Zheng
Norma Alonzo Palma
Mark Wingertzahn
Trials, 22
[22] A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant n patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)
Malchair, Pierre
Otero, Aurema
Giol, Jordi
Solanich, Xavier
Carnaval, Thiago
Fernandez-Nistal, Alonso
Sanchez-Gabriel, Ana
Montoto, Carmen
Lleonart, Ramon
Videla, Sebastian
TRIALS, 2022, 23 (01)
[23] A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
Fragoso-Saavedra, Sergio
Iruegas-Nunez, David A.
Quintero-Villegas, Alejandro
Garcia-Gonzalez, H. Benjamin
Nunez, Isaac
Carbajal-Morelos, Sergio L.
Audelo-Cruz, Belem M.
Arias-Martinez, Sarahi
Caro-Vega, Yanink
Calva, Juan Jose
Luqueno-Martinez, Veronica
Gonzalez-Duarte, Alejandra
Crabtree-Ramirez, Brenda
Crispin, Jose C.
Sierra-Madero, Juan
Belaunzaran-Zamudio, Pablo F.
Valdes-Ferrer, Sergio I.
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[24] A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
Sergio Fragoso-Saavedra
David A. Iruegas-Nunez
Alejandro Quintero-Villegas
H. Benjamín García-González
Isaac Nuñez
Sergio L. Carbajal-Morelos
Belem M. Audelo-Cruz
Sarahi Arias-Martínez
Yanink Caro-Vega
Juan José Calva
Verónica Luqueño-Martínez
Alejandra González-Duarte
Brenda Crabtree-Ramírez
José C. Crispín
Juan Sierra-Madero
Pablo F. Belaunzarán-Zamudio
Sergio I. Valdés-Ferrer
BMC Infectious Diseases, 20
[25] A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Smith, Keisha
Pace, Amy
Ortiz, Stephan
Kazani, Shamsah
Rottinghaus, Scott
TRIALS, 2020, 21 (01)
[26] A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Keisha Smith
Amy Pace
Stephan Ortiz
Shamsah Kazani
Scott Rottinghaus
Trials, 21

← 1 2 3 →